Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (trading symbol: TROV) on April 9, 2020. The report details a material definitive agreement entered into on the same date. Note: While the request metadata references "Cardiff Oncology, Inc.", the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC for a registered direct offering and concurrent private placement.
- Aggregate Gross Proceeds: Approximately $1.084 million (before estimated offering expenses).
- Securities Issued:
- 904,970 shares of Common Stock.
- Series K Pre-Funded Warrants to purchase up to 255,000 shares of Common Stock.
- Series L Warrants to purchase up to 1,159,970 shares of Common Stock.
- Pricing: The combined purchase price for each Share and one Series L Warrant is $0.935.
- Warrant Terms:
- Series K: Exercisable immediately; nominal exercise price of $0.01 per share (remainder pre-funded).
- Series L: Exercisable beginning six months after issuance; exercise price of $0.81 per share.
The filing does not provide specific data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
This filing represents a new capital raise event rather than a comparative financial period change. The primary material change is the dilution of existing shareholders through the issuance of new common stock and warrants, and the influx of approximately $1.084 million in gross proceeds.
Outlook, Risks, and Restrictions
- Lock-Up Period: The Company agreed to a 60-day restriction following the closing, during which it will not issue or agree to issue any shares of Common Stock or Common Stock equivalents, subject to certain exceptions.
- Closing Conditions: The transaction is subject to the satisfaction of specified customary closing conditions.
- Registration Status: The Common Stock and Series K Pre-Funded Warrants are registered under an effective Form S-3. The Series L Warrants are unregistered, offered pursuant to Section 4(a)(2) and Rule 506(b) exemptions.
Investor Verification Checklist
- Verify the final closing of the transaction and the actual net proceeds received after deducting offering expenses.
- Confirm the exact number of shares outstanding post-issuance to assess dilution impact.
- Review the definitive transaction documents (Exhibits 10.1, 10.2, and 10.3) for specific anti-dilution provisions and cashless exercise terms.
- Monitor the 60-day lock-up period to ensure no unauthorized equity issuances occur.